Skip to Content

PrandiMet Approval History

  • FDA approved: Yes (First approved June 23rd, 2008)
  • Brand name: PrandiMet
  • Generic name: repaglinide and metformin
  • Dosage form: Tablets
  • Company: Sciele Pharma, Inc. and Novo Nordisk Inc.
  • Treatment for: Diabetes, Type 2

PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Development History and FDA Approval Process for PrandiMet

Jun 24, 2008Approval FDA Approves PrandiMet, a Replaglinide and Metformin Fixed-Dose Combination Tablet for Treatment of Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.